Wegovy 2.4mg Compared to Mounjaro: What the Evidence Actually Shows

Step 1: Understand what each dose position actually represents

Wegovy's standard maintenance dose is 2.4mg semaglutide, reached after a gradual titration from 0.25mg over approximately 16 weeks. It is the ceiling dose in the original licensed schedule, though the MHRA approved a higher 7.2mg dose in January 2026 and a dedicated single-dose 7.2mg pen in April 2026. For most people starting Wegovy today, 2.4mg is still where treatment aims to settle.

Mounjaro's dose range runs from 2.5mg up to 15mg, also titrated in roughly four-week steps by the prescriber. The 2.5mg starting pen is a tolerability step, its job is to let your system adjust, not to drive significant weight loss. Therapeutic effect builds across the titration. So when people ask what 2.4mg Wegovy is equivalent to in Mounjaro terms, the honest answer is: it sits somewhere in the mid-range of Mounjaro's schedule, not at the top.

You can read more about how the conversion logic works across all doses on our Mounjaro equivalent dose to Wegovy page, which covers the full titration ladder in context. Neither medicine should be compared by milligram numbers alone, GLP-1 receptor agonists and dual GIP/GLP-1 agonists work differently at the receptor level, so a higher number in milligrams does not automatically mean a stronger effect.

Step 2: Look at what the trial data says, side by side

The table below draws from the two landmark licensing trials and from SURMOUNT-5, the direct head-to-head. Numbers are trial averages; individual results vary.

The trials were not identical in design, so direct percentage comparisons carry caveats. What the SURMOUNT-5 data adds is a controlled, same-trial comparison: tirzepatide produced greater average weight reduction than semaglutide 2.4mg. The gap narrows somewhat when Wegovy's newer 7.2mg dose is considered. Our Wegovy vs Mounjaro overview covers the wider evidence picture if you want to dig into the detail.

Step 3: Know what the comparison cannot tell you

Trial averages describe populations, not individuals. Someone who responds exceptionally well to semaglutide 2.4mg may achieve more than the 15% average; someone who tolerates tirzepatide poorly may not reach the results seen in SURMOUNT-1. Eligibility, medical history, other medicines, and tolerability all shape which option a prescriber recommends, and at what dose.

A quick practical check worth doing before any consultation: look up your current BMI using the NHS BMI calculator. Both medicines are licensed for adults with a BMI of 30 or above, or from 27 with at least one weight-related condition such as hypertension or type 2 diabetes. Having that number to hand takes under a minute and makes your consultation more productive.

If you are currently on Wegovy and considering a switch, or on Mounjaro and wondering whether 2.4mg semaglutide would be a step up or down, the Mounjaro to Wegovy dose conversion page walks through what that transition typically involves clinically. A prescriber at nume reviews every request against your full history, no auto-approvals, no skipping that step.

Step 4: What this means for switching or starting

If you are currently on Wegovy 2.4mg and wondering whether tirzepatide would offer more, you are asking a reasonable clinical question, the trial data suggests it might, for many people. Switching is not simply a dose-match exercise, though. Prescribers consider how long you have been on your current dose, how much weight you have lost, and whether side effects have been an issue.

People transferring to nume from another provider are reviewed against evidence of their current treatment; dose increases also require clinical sign-off. That process protects you as much as it does anything else. If you are on an early part of the titration and curious how the doses line up, our page on what Wegovy 1mg corresponds to in Mounjaro terms is a useful reference before your next conversation with a prescriber. You can see how our clinical team approaches these decisions on the clinical team page.

Pricing is a separate and fair question. Mounjaro's list price increased significantly from September 2025, and the two medicines now sit in broadly similar price territory at their respective maintenance doses in the private market, though exact figures vary by provider and dose. If you are weighing up a move to a higher tirzepatide dose, it is also worth reading about how Mounjaro 5mg compares to Wegovy so you have a clearer sense of where that dose sits relative to semaglutide before committing. Our Mounjaro and Wegovy price comparison covers the cost context without the sales gloss. The right starting point for either medicine is a consultation; start yours free here and a prescriber will take it from there.